Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.38 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2567586 | 0.78 | KMT2A (0.34) | ALDH1A1 | |
| SCHEMBL1991174 | 0.78 | RRM2 (0.30) | AGBL2 | |
| SCHEMBL7691715 | 0.78 | MAPT (0.32) | ERN1ALDH1A1 | |
| SCHEMBL22713504 | 0.78 | HTR5A (0.31) | AGBL2ALDH1A1 | |
| SCHEMBL2084862 | 0.78 | AGBL2 (0.44) | AGBL2 | |
| SCHEMBL3144721 | 0.78 | LMNA (0.32) | ERN1AGBL2 | |
| SCHEMBL16302869 | 0.78 | CCR1 (0.34) | ERN1ALDH1A1 | |
| SCHEMBL22084407 | 0.78 | ERN1 (0.35) | ERN1 | |
| SCHEMBL19815704 | 0.77 | AGBL2 (0.32) | AGBL2 | |
| SCHEMBL24423127 | 0.75 | KIF11 (0.35) | ERN1AGBL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486281-B2 | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2025-12-02 | — | — | US | disclosed |
| US-12358887-B2 | IKAROS Zinc Finger Family degraders and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| WO-2025106482-A1 | COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) | 2025-05-22 | — | — | WO | disclosed |
| CN-119930578-A | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | 细胞基因公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| CN-114269729-B | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | 细胞基因公司 | 2025-01-17 | — | — | CN | disclosed |
| US-20240383904-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-11-21 | — | — | US | disclosed |
| EP-4464703-A2 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| EP-4245756-B1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2024-10-09 | — | — | EP | disclosed |
| CN-118724867-A | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | 细胞基因公司 | 2024-10-01 | — | — | CN | disclosed |
| EP-1613613-A4 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC (CA) | 2009-03-25 | — | — | EP | disclosed |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED CORPORATION (CA) | 2008-10-16 | — | — | US | disclosed |
| WO-2008117050-A1 | PYRAZOLYL-AMINO-SUBSTITUTED PYRAZINES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-10-02 | — | — | WO | disclosed |
| US-7291631-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| US-20070015807-A1 | Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists | SCHERING CORPORATION | 2007-01-18 | — | — | US | disclosed |
| US-20070015807-A1 | Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists | SCHERING CORPORATION | 2007-01-18 | — | — | US | disclosed |
| WO-2007001975-A1 | PIPERIDINE DERIVATIVES USEFUL AS HISTAMINE H3 ANTAGONISTS | SCHERING CORPORATION (US) | 2007-01-04 | — | — | WO | disclosed |
| EP-1613613-A2 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004091518-A2 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2004-10-28 | — | — | WO | disclosed |
| US-20040209921-A1 | CXCR4 chemokine receptor binding comounds | ANORMED CORPORATION (CA) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358887-B2 | IKAROS Zinc Finger Family degraders and uses thereof | IKZF2, IKZF1, IKZF3 | ERN1 1254/4885AGBL2 1557/4885ALDH1A1 3576/4885 |
| US-20240383904-A1 | HETEROCYCLIC COMPOUNDS | MAGI3, MAG, MAGT1 | ERN1 1785/4885AGBL2 644/4885ALDH1A1 1488/4885 |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | ERN1 774/4885AGBL2 4621/4885ALDH1A1 411/4885 |
| US-20040209921-A1 | CXCR4 chemokine receptor binding comounds | CXCR4, CXCR1, CXCR3 | ERN1 3367/4885AGBL2 3707/4885ALDH1A1 357/4885 |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | CXCR4, CXCR1, CXCR3 | ERN1 3904/4885AGBL2 3675/4885ALDH1A1 424/4885 |
| US-20070015807-A1 | Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists | HRH3, HRH4, CHRM2 | ERN1 3925/4885AGBL2 3229/4885ALDH1A1 1382/4885 |
| US-12486281-B2 | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | CPT1A, GOT2, IDH2 | ERN1 3300/4885AGBL2 3912/4885ALDH1A1 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.